Why it's here: A once-daily synbiotic pairing chicory root inulin (211 mg) and potato resistant starch (100 mg) with a three-strain probiotic blend containing Akkermansia muciniphila, Clostridium butyricum, and Bifidobacterium infantis. The strain selection has a coherent rationale — A. muciniphila has a documented GLP-1 mechanism through the P9 protein identified by Yoon and colleagues in 2021, and C. butyricum produces butyrate. CoreAge publishes its fiber amounts, cold-ships the product to protect probiotic viability, and states third-party lot testing for identity, potency, microbial contamination, and heavy metals.

What the evidence does not show: CoreAge does not publish CFU counts per strain, so you cannot compare the dose against published research. The 211 mg of inulin is far below the multi-gram doses used in most fiber studies. The A. muciniphila GLP-1 work is largely preclinical, and there are no published clinical trials of this specific formulation. No refund policy is published on the product page.

Why it's here: The unglamorous option with the best data. Published research describes gel-forming non-fermented psyllium, dosed just before meals, as effective in facilitating weight loss in overweight and obese participants, and a separate trial in healthy volunteers found it contributed to greater fullness and less hunger between meals. It works mechanically — forming a viscous gel that slows gastric emptying — so it does not depend on speculative microbiome effects, and it causes far less gas than fermentable fibers.

What the evidence does not show: Effects on body weight are modest, timing matters (the research doses before meals), and it does not raise GLP-1 through fermentation because it is largely non-fermented. It must be taken with a full glass of water — there is a real choking and obstruction risk otherwise. Adherence is the practical problem: it is unpleasant to drink.

Why it's here: The only product here delivering fiber at gram rather than milligram doses — 6 g per serving from a blend including oat beta glucan, Solnul resistant potato starch, and Sunfiber. Fermentable fiber is the best-supported mechanism in this category: colonic fermentation produces short-chain fatty acids, and SCFAs are an established stimulus for GLP-1 secretion from intestinal L-cells. At 6 g, the dose is within the range fiber research actually uses.

What the evidence does not show: The individual amounts within the four-part blend are not published. There are no published trials of this specific product. Endogenous GLP-1 released through fermentation is short-lived and physiological, not comparable to a long-acting receptor agonist. And you could reach 6 g of fiber through food for a fraction of the price.

Why it's here: Pendulum publishes organism counts — 100 million AFU per capsule on its standalone Akkermansia product — which is the single most useful disclosure a probiotic company can make, and most do not. It is the most established brand in the Akkermansia space with a genuine research footprint, and its strain approach mirrors the mechanism described in the published A. muciniphila literature.

What the evidence does not show: The GLP-1 mechanistic work on A. muciniphila remains largely preclinical. Per-strain counts in the multi-strain GLP-1 blend are less clearly published than for the standalone product. Company-associated research is not independent replication. The product line is confusing, with several overlapping SKUs at different prices.

Why it's here: The ingredient with the strongest human evidence base in this whole category. A meta-analysis concluded berberine can improve obesity and hyperlipidemia by reducing triglycerides, total cholesterol and LDL while increasing HDL, and reduce insulin resistance. A 2025 randomized clinical trial in JAMA Network Open assessed it for visceral adipose tissue and liver fat in diabetes-free individuals.

What the evidence does not show: The "nature's Ozempic" framing is not supported by any of that research — berberine trials show modest metabolic changes, not 15–21% body weight reduction. It requires 900–2,000 mg per day in three or four divided doses, which most people will not sustain. It has significant CYP3A4 drug interactions, commonly causes GI side effects, and published research has documented variability in actual content between commercial preparations.

Why it's here: The lowest-priced branded product here, combining berberine HCl, chromium, green tea extract standardised to 50% EGCG, gymnema sylvestre, and curcumin at 95% curcuminoids with probiotic content. Using standardised extracts rather than raw botanical powders is better practice, and it is widely available through major retailers.

What the evidence does not show: Per-ingredient amounts are not published, so the formula cannot be evaluated against the underlying research at all — and with this many actives, none can plausibly be at a research dose. Berberine research alone uses 900–2,000 mg per day. Curcumin without a bioavailability enhancer is poorly absorbed. Its "GLP-1 agonist support" branding is exactly the naming practice public-health researchers have criticised.

Why it's here: Built on three branded, patented botanical extracts — Supresa saffron, Morosil red orange, and Eriomin lemon — each with published research attached to the specific branded form. That is genuinely better practice than unstandardised botanical powders, because you know what was studied.

What the evidence does not show: Per-capsule amounts are not consistently published, which undermines the entire point of using branded ingredients — you cannot confirm the formula delivers the studied doses. Ingredient trials are typically small and often supplier-funded. There are no independent trials of the finished formula. And at roughly $79–$90 it is the most expensive product here by a wide margin.

Why it's here: Included as a contrast rather than a supplement recommendation. Plenity is an FDA-cleared prescription medical device — cleared through the De Novo pathway (DEN180060) — meaning safety and effectiveness data for its stated use were actually reviewed. It is a non-absorbed hydrogel that creates volume in the stomach. If you want to understand the gap between "supplement" and "reviewed by a regulator," this is what the second category looks like.

What the evidence does not show: Device clearance is a lower bar than drug approval, results are modest relative to GLP-1 medications, it requires a prescription, and it does not act on GLP-1 pathways at all. It is here to illustrate a regulatory distinction, not because it is a better version of the products above it.